Lilly
Jane Calloway, 317-651-5870
    or
ICOS
Lacy Fitzpatrick, 425-415-2207

  An Independent Clinical Trial Shows That Cialis Was Preferred Over
           Viagra(R) and Levitra(R) Because of its Extended
                        Period of Effectiveness

Lilly ICOS LLC (NYSE:LLY)(Nasdaq:ICOS) -- In an analysis of clinical
data 80 percent of men with erectile dysfunction (ED) chose to attempt
sexual intercourse after four and up to 24 hours after taking
Cialis(R) (tadalafil) over a 12-week period. These data, along with
other new studies presented at the 6th European Society for Sexual
Medicine (ESSM), suggest that men take full advantage of the extended
period of effectiveness of Cialis, a new oral treatment for ED
developed by Lilly ICOS.

According to the product prescribing information in Europe, Cialis can
be taken as early as 30 minutes and up to 12 hours prior to sexual
activity and its effects may persist up to 24 hours post-dose.

"What these studies tell us is that, given the chance, men will fully
utilize the opportunity to be intimate with their partners beyond the
time frame that other oral ED treatments may offer," said Ian Eardley,
M.D., from St. James's University Hospital, Leeds, U.K., who presented
these data for the first time in Europe. "The extended period of
effectiveness of Cialis allows couples to return to the spontaneity of
a more normal sex life."

The results support an independent, head-to-head study announced at
ESSM, which showed that when men were offered the opportunity by their
physician to try all three currently available PDE5 inhibitors, 45
percent preferred Cialis, compared to 30 percent preferring vardenafil
(Levitra(R))and 13 percent preferring sildenafil (Viagra (R)). Hartmut
Porst, M.D., a private urological/andrological physician in Hamburg,
Germany and Associate Professor of Urology, and one of the world's
leading ED specialists, conducted this independent study, concluding
Cialis was preferred because of its extended period of
effectiveness(1).

Time Distribution of Sexual Intercourse Attempts -- Analysis Findings

Embargoed until 12:01 p.m., Central European Time, Tuesday, Nov. 18,
2003

An integrated analysis from 11 multi-center, randomized, double-blind,
placebo-controlled 12-week Phase III studies evaluated 2,102 men
taking 10 mg and 20 mg Cialis or placebo. The analysis sought to
analyze when couples choose to have sexual intercourse when they were
not restrained by the length of time their ED medication lasted and
whether they took advantage of a longer period of effectiveness.

In the studies, men were instructed to take the medication prior to
sex but without guidance or restriction on the timing of sexual
activity after dosing. The men were also asked to keep diaries
detailing when sexual intercourse was attempted. The data showed that
82 percent of men attempted intercourse after four hours and up to 36
hours after taking Cialis at least once over the 12-week treatment
period. In fact, 59 percent of men made attempts beyond 12 hours and
up to 36 hours after taking Cialis.

Cialis is Effective for Up to 24/36 Hours in Men with ED - Analysis
Findings

Embargoed until 12:01 p.m., Central European Time, Wednesday, Nov. 19,
2003

Results from a separate integrated analysis of 11 studies sought to
determine the effectiveness of Cialis in men with ED at all time
points they chose to have intercourse from 30 minutes to 36 hours. In
these multi-center, randomized, double-blind 12-week efficacy studies,
Cialis was taken without restriction on time to attempt sexual
intercourse.

This analysis showed that in 580 men taking 20 mg Cialis, 73 percent
of attempts were successful in response to stimulation between 12 and
24 hours after dosing. 73 percent of intercourse attempts were also
successful during the period 24 to 36 hours after dosing.

"These data support the effectiveness of 10 mg and 20 mg Cialis in men
with ED from 30 minutes to up to 24 hours after taking the tablet,"
said lead author Dimitrios Hatzichristou, M.D., Associate Professor of
Urology/Andrology, University Thessaloniki, Greece, and current
President of the ESSM. "The extended period of effectiveness of Cialis
can give men and their partners the freedom to choose when to attempt
intercourse for up to 24 and even 36 hours."

Gordon Steel, married for 33 years, explains: "When I first developed
ED, my wife and I thought that because we had been married for such a
long time that it didn't matter anymore. But when we spoke about it we
both felt the need for a good sex life. The treatment I'm on now -
Cialis - allows us to have the sex life we used to have, without
reminding me of my ED. Obviously we are both happy now."

Cialis was well tolerated in both studies. Common adverse events were
headache, muscle ache, backache and upset stomach.

End of embargoed information.

Independent, Head-to-Head Study of Three PDE5 Inhibitors - Study
Findings

Results from an independent, head-to-head study investigating patient
preference for Cialis, vardenafil (Levitra) or sildenafil (Viagra),
were also presented at ESSM. In an open-label, randomized crossover
study, Cialis was preferred more often than either Viagra or Levitra
for those expressing a preference. The study was conducted
independently by Professor Hartmut Porst.

In this trial, patients received at least six consecutive doses each
of Viagra, Cialis, and Levitra. Patients were asked on completion of
this phase of the trial to choose one of the three treatments for
continued therapy as an indication of their preference. Of the 150
participants, 45 percent preferred Cialis, 30 percent Levitra and 13
percent Viagra. Only 12 percent expressed no preference but these
patients responded poorly to all three drugs. 96 percent of those
preferring Cialis stated they did so because of the greater period of
effectiveness.

In addition, of those stating efficacy as a reason for their
preference, 43 percent preferred Cialis, 36 percent Levitra and 20
percent Viagra.

Commenting on his results, Professor Porst said, "These results are
the first three-way preference data comparing the three PDE5
inhibitors. All the drugs are effective, but Cialis appears to offer
men a greater degree of choice and flexibility in intimacy with their
partners."

All three PDE5 inhibitors showed effectiveness in treating ED and
showed the known pattern of side effects most commonly reported for
each drug, specifically, headache, flushing and upset stomach.

About ED

ED is defined as the consistent inability to attain and maintain an
erection sufficient for sexual intercourse. ED affects an estimated
152 million men and their partners worldwide(2). Up to 80 percent of
ED cases are caused by physiological conditions, including
cardiovascular disease and diabetes, with psychological factors
accounting for the remaining 20 percent. In many cases, however, both
psychological and physical factors contribute to the condition(3).

Cialis is available in more than 45 countries worldwide, including
Europe, Brazil, Mexico, Australia, New Zealand and Saudi Arabia.

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly
and Company, developed tadalafil for the treatment of sexual
dysfunction.

Eli Lilly and Company, a leading innovation-driven corporation, is
developing a growing portfolio of best-in-class pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organisations. Headquartered in Indianapolis, Indiana, Lilly provides
answers -- through medicines and information - for some of the world's
most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in
both protein-based and small molecule therapeutics. ICOS combines its
capabilities in molecular, cellular and structural biology,
high-throughput drug screening, medicinal chemistry and gene
expression profiling to develop highly innovative products expected to
have significant commercial potential. ICOS applies its integrated
approach to erectile dysfunction and other urologic disorders,
psoriasis, sepsis and inflammatory diseases. ICOS' strategy targets
multiple therapeutic areas with drugs that act through distinct
molecular mechanisms, increasing ICOS' opportunities to market
breakthrough products.

Certain of the matters discussed herein with respect to clinical
studies and ICOS and Lilly's products may constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements are based on
current expectations, estimates and projections about the industry,
management beliefs and certain assumptions made by the management.
Investors are cautioned that matters subject to forward-looking
statements involve risks and uncertainties, including economic,
competitive, governmental, technological and other factors discussed
in the two companies' respective filings with the Securities and
Exchange Commission, which may affect the business and prospects of
the two companies. More specifically, there can be no assurance that
this product will achieve commercial success or that competing
products will not pre-empt any market opportunity that might exist for
the product.

(1) A comparator trial between Sildenafil, Tadalafil and Vardenafil --
    Preliminary results in 150 patients Abstract presented at 6th
    European Society for Sexual Medicine. Istanbul, Turkey 16th-19th
    November 2003.

(2) Aytac IA, McKinlay JB, Krane RJ. The Likely Worldwide Increase in
    Erectile Dysfunction Between 1995 and 2025 and Some Possible
    Policy Consequences. BJU Int 1999; 84: 50-56.

(3) Impotency Information from NIH. NIH Publication No. 95-3923.1995